Calcium folinate pentahydrate
Head and Neck Cancer
Incyte CorporationSmall moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
114 Active assets in the Head and Neck Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
Cyclophosphamide Zelluna Immunotherapy AS | Phase 3 | BB |
Epirubicin Thomas Jefferson University | Phase 3 | BB |
Pembrolizumab Thomas Jefferson University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Calcium folinate pentahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →